WuXi Biologics trip notes: valuation attractiveness has rebounded, and commercialization plus capacity expansion validate the “follow-the-molecule” model

Overview

This report is Morgan Stanley's Asia Pacific trip takeaways on WuXi Biologics Cayman Inc (2269.HK). The report focuses on the rebound in investor attention to the large-molecule CDMO sector, the company's 2026 revenue and gross margin guidance, segment growth, capacity expansion, commercialization of single-use technology, manufacturing stickiness, and biosimilar revenue contribution. The report also discloses the company as Overweight, the industry view as Attractive, and a target price of HK$50.00.

Core views

The core view is that WuXi Biologics' valuation has returned to a less demanding level, and investors are beginning to revalidate its "follow-the-molecule" business model. The company expects 2026 revenue growth of 13-17%; if FX is not a drag, growth could be about 3 percentage points higher. Driven by bispecific/multispecific antibodies, ADCs, mAbs, and biosimilars, the growth structure remains resilient. Commercial manufacturing, single-use technology scale-up, and customer conversion from research services help deepen manufacturing stickiness.

Analysis framework

The report is mainly a trip-communication takeaway note, with analysis based on management guidance, investor questions, peer comparisons, business segment growth, capacity planning, and valuation assumptions. The valuation uses a DCF base case and refers to Morgan Stanley's relative rating framework to explain the meaning of the Overweight rating.

Methodology notes

• Valuation methodDCF

  Base-case discounted cash flow valuation

  The report uses a discounted cash flow method, assuming WACC of 8.4%, perpetual growth rate of 4%, and HKD:RMB exchange rate of 0.9.

• Rating systemMorgan Stanley relative rating

  Overweight

  Overweight means that over the next 12-18 months, on a risk-adjusted basis, the stock's expected total return is higher than the average total return across the analyst's industry coverage universe.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• WuXi Biologics Cayman Inc (2269.HK)

  The report's subject company; the core large-molecule CDMO name

  Strengths

  Valuation at about 24x 2026 PE, with investment interest rebounding; 2026 revenue growth guidance of 13-17%; bispecific/multispecific antibodies, ADCs, and mAbs continuing to grow; capacity expansion and single-use technology scale-up supporting long-term commercial delivery; more than 50 molecules developed by Research Services may strengthen customer stickiness.

  Weaknesses

  The 2025 gross margin base is relatively high due to FX impacts; 2026 revenue and gross margin are sensitive to USD depreciation, customer project timing, and the intensity of global R&D outsourcing.

  Comparison

  Investors continue to compare WuXi Bio, Samsung Bio, and Lonza in the large-molecule CDMO space; the report believes Samsung's recent strike has limited direct read-through to WuXi Biologics, because it mainly affects commercial manufacturing contracts and the probability of transfer is low.

  Risks

  Further slowdown in biologics projects, reduced R&D outsourcing intensity, FX drag, and commercial contract execution below expectations.

• Samsung Bio

  Peer comparison target in large-molecule CDMO

  Strengths

  One of the main large-molecule CDMO names that investors compare.

  Weaknesses

  The recent labor strike mainly affects commercial manufacturing contracts.

  Comparison

  The report believes its strike has limited impact on transferable orders for WuXi Biologics, because those commercial contracts are unlikely to be moved out.

  Risks

  Labor events may affect market discussions about CDMO supply stability, but the report does not view them as a primary upside catalyst for WuXi Biologics.

• Lonza

  Peer comparison target in large-molecule CDMO

  Strengths

  An important reference in the global CDMO investor comparison framework.

  Weaknesses

  The report does not provide specific weaknesses.

  Comparison

  Together with WuXi Bio and Samsung Bio, it forms the investment comparison group for the large-molecule CDMO sector.

  Risks

  The report does not provide specific risks.

Key data

• Stock ratingOverweightThe report disclosed an Overweight rating.
• Industry viewAttractiveMorgan Stanley's industry view is Attractive.
• Target priceHK$50.00The target-price history shows a target price of 50 on 2026-02-11, and the valuation snapshot also shows HK$50.00.
• Closing priceHK$33.86The valuation snapshot shows a 2026-05-13 closing price of HK$33.86.
• Implied upsideabout 47.7%Calculated using the HK$50.00 target price and HK$33.86 closing price.
• 2026 revenue growth guidance13-17%Excluding USD depreciation, revenue growth could be about 3 percentage points higher.
• Capacity planabout 300,000L to about 370,000LYear-end drug-substance capacity is about 300,000L and is expected to reach about 370,000L in 2029.
• Current yield8g/LCapacity expansion is accompanied by yield improvement.
• Valuation multipleabout 24x 2026 PEThe report says valuation has reached a less demanding level.

Impact & implications

For investors, the report emphasizes that WuXi Biologics' investment case is shifting from valuation re-rating to validation of commercialization capability. If the 2026 revenue guidance, gross margin stability, single-use commercialization contracts, capacity utilization, and biosimilar ramp-up are achieved, the Overweight rating and HK$50.00 target price will have stronger support; otherwise, if global biologics R&D project momentum slows or outsourcing intensity weakens, revenue and margin expectations may come under pressure.

Risks

• Global biologics projects at pharmaceutical and biotech companies slow further.
• R&D services outsourcing intensity declines.
• USD depreciation continues to affect revenue growth and gross margin comparability.
• Biotech funding recovery is weaker than expected, and CMO project conversion falls short of expectations.
• Commercial contracts, single-use technology scale-up, or biosimilar revenue ramp-up fall short of expectations.
• Morgan Stanley discloses that it has, or seeks to have, investment banking relationships with covered companies, and investors should treat this report as only one factor in their investment decision.

What to watch

• Whether 2026 revenue growth reaches the 13-17% guidance range.
• Actual growth and gross margin stability excluding FX effects.
• Whether the segment growth ranking of bispecific/multispecific antibodies, ADCs, and mAbs continues.
• The pace of advancing from about 300,000L year-end capacity toward the about 370,000L plan for 2029.
• The number of commercial contracts using single-use bioreactors and continuous perfusion manufacturing, and their cost performance.
• The proportion of molecules developed by Research Services that, after licensing, choose WuXi Biologics as their commercial manufacturing partner.
• The ramp-up speed of biosimilar revenue after originator biologics lose market exclusivity and patent protection.
• Whether Samsung Bio's labor dispute triggers a re-evaluation of customer supply chains.